Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Payables (2016 - 2025)

Historic Payables for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $3.0 million.

  • Cytosorbents' Payables rose 2980.39% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 2980.39%. This contributed to the annual value of $3.3 million for FY2024, which is 1215.54% down from last year.
  • Per Cytosorbents' latest filing, its Payables stood at $3.0 million for Q3 2025, which was up 2980.39% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Payables ranged from a high of $4.8 million in Q1 2022 and a low of $1.7 million during Q4 2022
  • Its 5-year average for Payables is $2.9 million, with a median of $3.0 million in 2023.
  • Data for Cytosorbents' Payables shows a peak YoY increase of 18766.41% (in 2022) and a maximum YoY decrease of 4099.7% (in 2022) over the last 5 years.
  • Over the past 5 years, Cytosorbents' Payables (Quarter) stood at $2.8 million in 2021, then plummeted by 41.0% to $1.7 million in 2022, then skyrocketed by 129.71% to $3.8 million in 2023, then dropped by 12.16% to $3.3 million in 2024, then dropped by 9.13% to $3.0 million in 2025.
  • Its Payables stands at $3.0 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.3 million for Q1 2025.